Biotech uni­corn's 'brain' at­tracts a $115M mega-round as in­vestors em­brace AI up­start

Ar­ti­fi­cial in­tel­li­gence in drug de­vel­op­ment is still gain­ing mo­men­tum. Just ask Benev­o­len­tAI, which has brought in a new $115 mil­lion round for its tech­nol­o­gy that promis­es to process vast amounts of bio­science in­for­ma­tion and churn out new dis­cov­er­ies.

Backed by new, undis­closed in­vestors from the Unit­ed States as well as ex­ist­ing sup­port­ers like Wood­ford In­vest­ment Man­age­ment, the round puts Lon­don-based Benev­o­len­tAI at a pre-mon­ey val­u­a­tion of $2 bil­lion. The syn­di­cate fea­tures a mix of fam­i­ly of­fices and some strate­gic back­ers but not “more tra­di­tion­al VCs,” TechCrunch re­ports.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER